Estimating the Level of Interleukin-2 in Blood Serum and its Role in Distinguishing Between Early and Late Stages of Kidney Disease
DOI:
https://doi.org/10.46966/msjar.v5i2.190Keywords:
Kidney disease, Interleukin2, eGFRAbstract
Background: Interleukin 2 (IL-2) is a type of cytokine. It have essential role in proliferation and regulation of T cell. In kidney disease, IL-2 play a role in regulation of immune response. This study aims to evaluate the level of IL-2 and its relationship to the five stages of the disease. Subject and method: Ninety blood samples are taken from participant in this study and it divided into two groups, control group (30) samples and kidney disease group (60) samples. The parameters were measured include; (IL- 2, urea, creatinine), and GFR was estimated. Statistical analysis was performed for all parameters under the study. Results: The low level of IL-2 have a high significance difference in disease group as compared to control group (P=0.001), also there was a positive correlation between IL-2 and kidney disease stages. Furthermore, there were significant different in the mean serum levels of IL-2 among GFR stages. ROC curve give a good result in differentiation patients from control. Conclusion: it is possible to rely on the level of IL-2 in the blood to distinguish between the early and late stages of the disease, as it plays an important role in tracking the disease and its development.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Hussein Ali Abood, Dunia Tahseen Nema AL-Aridhi, Ammar Lateef Hussein
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
